Nieuws en video's - KIADIS - Pagina 2

Data presented support the potential of combining oncolytic virotherapy along with PM21-NK cell adoptive therapy against lung cancer Amsterdam, The Netherlands, November 12, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS) , a clinical stage biopharmaceutical company developing innovative cell-based medicines for the treatment of life-threatening diseases, today announces that new data related to its K-NK cell therapy platform will be...

This is a joint press release by Sanofi (" Sanofi ") and Kiadis Pharma N.V. (" Kiadis "), pursuant to the provisions of Section 4, paragraphs 1 and 3, Section 5, paragraph 1 and Section 7, paragraph 4 of the Netherlands Decree in Public Takeover Bids (Besluit openbare biedingen Wft) (the " Decree ") in connection with the intended public offer by Sanofi for all the issued and outstanding ordinary shares in the capital of Kiadis (the " Offer "). This announcement does not constitute an offer, or...

Amsterdam, The Netherlands, October 26, 2020 – Kiadis Pharma N.V. ("Kiadis" or the "Company") (Euronext Amsterdam and Brussels: KDS) , a clinical-stage biopharmaceutical company developing innovative NK-cell-based medicines for the treatment of life-threatening diseases, today announces that a poster was accepted for presentation at the Society for Immunotherapy of Cancer (SITC) annual meeting being held virtually from November 9-14, 2020. The details of the poster presentation are as follows:...

9% secured convertible bonds replace €5 million in Kreos debt Conversion price €2 per share Remaining Kreos debt facilities reduced to €1.6 million Amsterdam, The Netherlands, October 1, 2020 – Kiadis Pharma N.V. ("Kiadis" or the "Company") (Euronext Amsterdam and Brussels: KDS) , a clinical-stage biopharmaceutical company developing innovative NK-cell-based medicines for the treatment of life-threatening diseases, announces the placement of €5 million of secured convertible bonds to...

K-NK002 (HSCT): IND approved to enter Phase 2 development K-NK003 (AML R/R): IND approved and multiple patients enrolled for Phase 1 investigator initiated trial for treatment of relapsed/refractory acute myeloid leukemia (R/R AML) K-NK004 (MM): pre-clinical engineered product candidate partnered with Sanofi; €17.5M upfront, potential total deal value of >€875 million, plus royalties K-NK-ID101 (COVID-19/respiratory): research consortium established, investigator sponsored Phase 1/2 IND...

Collaboration marks first contractual partnership with supplier of universal donor material Amsterdam, The Netherlands, September 28, 2020 – Kiadis Pharma N.V. ("Kiadis" or the "Company") (Euronext Amsterdam and Brussels: KDS) , a clinical-stage biopharmaceutical company developing innovative NK-cell-based medicines for the treatment of life-threatening diseases and Gulf Coast Regional Blood Center (GCRBC), a primary supplier of blood components to more than 170 hospitals and health care...

Funding for COVID-19 research and development program (K-NK-ID101), to investigate the potential to establish it as a universal countermeasure to fight COVID-19 and future pandemics Funding obtained from the Advanced Regenerative Manufacturing Institute’s BioFabUSA program, in partnership with the United States Department of Defense (DoD) Provides foundation for evaluating K-NK-ID101 as a protection for immunocompromised and high-risk patients against multiple seasonal respiratory infections,...

Amsterdam, The Netherlands, September 14, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS) , a clinical-stage biopharmaceutical company developing innovative cell-based medicines for the treatment of life-threatening diseases, today announces a collaboration with the Abigail Wexner Research Institute (AWRI) at Nationwide Children’s Hospital to develop Kiadis-NK cells (K-NK cells) as a post-exposure pre-emptive therapy for COVID-19. The U.S....

Company announces Notice of Results for the six months ended June 30, 2020 Amsterdam, The Netherlands, September 3, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS) , a clinical stage biopharmaceutical company developing innovative cell-based medicines for life-threatening diseases, announces its investor events for September 2020. Interim results Kiadis will be issuing its interim results for the six months ended June 30, 2020 at 7:00 CEST /...

New data will be presented in an e-poster today at the Virtual Edition of the 46th EBMT Annual Meeting Amsterdam, The Netherlands, August 29, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS) , a clinical stage biopharmaceutical company developing innovative cell-based medicines for the treatment of life-threatening diseases, today announces that new data supporting the Company’s NK cell therapy is being presented at the 46 th Annual Meeting...

Initiates new COVID-19 research and development program (K-NK-ID101) Expands the application of Kiadis’ K-NK technology into infectious diseases Announces collaboration with five premier Dutch institutions: Viroclinics-DDL; Harbour BioMed Netherlands; Sanquin Bloedvoorziening; Erasmus Medical Center; and the Utrecht University, each contributing a unique strength in virology and COVID-19 research and know how Submitted grant application with US government Amsterdam, The Netherlands, August 17,...

CD38 KO NK cell therapy has the potential to maximize the efficacy of anti-CD38 against multiple myeloma Amsterdam, The Netherlands, July 22, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS) , a clinical stage biopharmaceutical company developing innovative cell therapeutics for life-threatening diseases, today announces publication of an article in Blood, Journal of the American Society of Hematology. The article describes the synergy of...

Senior executives with extensive biotechnology and pharmaceutical industry, science, innovation and business development experience Bringing unique capabilities to unlock broad potential of Kiadis platform Amsterdam, The Netherlands, July 13, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS) , a clinical stage biopharmaceutical company developing innovative NK-cell therapeutics for patients with life-threatening diseases, today announces that...

Combination of Kiadis’ CD38 knock out K-NK cells with Sanofi’s anti-CD38 antibody Sarclisa® enables optimal tumor cell killing, and offers a potential first-in-class treatment for patients with multiple myeloma Kiadis receives €17.5 million up front payment; potential for up to €857.5 million in preclinical, clinical, regulatory and commercial milestone payments, and up to double-digit royalties Kiadis to hold conference call with investors and analysts at 16:00 CET today Amsterdam, The...

Amsterdam, The Netherlands, July 2, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS) , a clinical stage biopharmaceutical company, today announces that Kiadis will present at the Solebury Trout & Venrock EU Virtual Summer Event on Tuesday, July 7, 2020 at 12:00pm EDT. Kiadis contacts Kiadis: Maryann Cimino, Sr. Manager, Corporate Affairs Tel: +1 (617) 710-7305 [email protected] LifeSpring LifeSciences Communication: Leon Melens (Amsterdam)...

Amsterdam, The Netherlands, June 25, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS) , a clinical-stage biopharmaceutical company, announces that at its Annual General Meeting held today at 10:00 CEST, all resolutions were duly passed by the shareholders. About Kiadis Founded in 1997, Kiadis is building a fully integrated biopharmaceutical company committed to developing innovative therapies for patients with life-threatening diseases. With...

Amsterdam, The Netherlands, June 25, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS) , a clinical stage biopharmaceutical company, and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital (OSUCCC-James), today announced that the first patient has been enrolled and treated in a phase I, first-in-human clinical trial in patients with relapsed/refractory acute myeloid leukemia (“R/R AML”) with...

Amsterdam, The Netherlands, June 17, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS) , a clinical stage biopharmaceutical company, today announces that Kiadis will present at the Virtual European Biotech Investor Day 2020 hosted by Solebury Trout, Goodwin, Deutsche Bank and Nasdaq on Thursday, June 25, 2020 at 1:30pm EDT. The presentation will be webcast live and may be accessed by visiting the "For Investors" section of the Company's...

3 presentations related to Kiadis’ K-NK cell therapy platform will be presented today at the 25th Congress of the European Hematology Association An oral presentation (abstract #S284) shows clinical data that K-NK cells persist and proliferate in vivo A poster presentation (abstract #EP1487) presents data that demonstrate uniformity of K-NK cells expanded with FC21 (as used in past clinical trials) or PM21 (industrial platform to be used in future clinical trials including NK-REALM), which are...

A poster presentation (abstract 3025) demonstrates results of multiple FC21-NK infusions in R/R AML patients with CNS disease, treated in an investigator-initiated Phase I/II study An abstract accepted for publication (abstract e15018) presents pre-clinical data demonstrating how a CD38 knock-out of off-the-shelf FC21-NK cells limits NK cell fratricide and enhances the overall activity against multiple myeloma cells in presence of an anti-CD38 antibody An additional poster presentation (abstract...